Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

M. Moehler, A. Maderer, P. C. Thuss-Patience, B. Brenner, J. Meiler, T. J. Ettrich, R. D. Hofheinz, S. E. Al-Batran, A. Vogel, L. Mueller, M. P. Lutz, F. Lordick, M. Alsina, K. Borchert, R. Greil, W. Eisterer, A. Schad, J. Slotta-Huspenina, E. Van Cutsem, S. Lorenzen

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)'. Together they form a unique fingerprint.

Medicine & Life Sciences